Regeneron Pharmaceuticals, Inc. (REGN) - What Are Investment Firms Thinking About This Stock?

Key Points

• Analysts remain broadly positive: Regeneron has a “Moderate Buy” consensus from 31 analysts, with 22 buys, eight holds and one strong buy. The average 12-month price target is $846.28, including TD Cowen’s raised target of $980.
• Business momentum is strong but earnings uncertainty remains: Recent results beat estimates, with revenue rising 16.7% year over year, while Dupixent growth and positive clinical-trial results support the longer-term outlook. However, analysts see less evidence of a likely beat ahead of next week’s quarterly report.
• Institutional ownership is substantial, while insiders have been selling: Institutional investors and hedge funds own 83.31% of REGN, including a new $5.68 billion BlackRock stake. Insiders sold $6.5 million of shares over the past 90 days, and valuation concerns could limit near-term upside.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the thirty-one analysts that are covering the company, Marketbeat reports. Eight equities research analysts have rated the stock with a hold recommendation, twenty-two have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month target price among brokerages that have issued ratings on the stock in the last year is $846.28.

A number of equities research analysts recently commented on the company. Robert W. Baird upped their target price on Regeneron Pharmaceuticals from $742.00 to $761.00 and gave the company a "neutral" rating in a research report on Friday, July 31st. TD Cowen lifted their price target on Regeneron Pharmaceuticals from $960.00 to $980.00 and gave the company a "buy" rating in a research note on Wednesday. Morgan Stanley upped their price objective on shares of Regeneron Pharmaceuticals from $758.00 to $779.00 and gave the stock an "equal weight" rating in a research report on Wednesday, October 7th. Leerink Partners raised their target price on Regeneron Pharmaceuticals from $641.00 to $824.00 and gave the company a "market perform" rating in a research report on Monday, August 17th. Finally, Sanford C. Bernstein boosted their price target on shares of Regeneron Pharmaceuticals from $753.00 to $756.00 and gave the stock a "market perform" rating in a research report on Friday, August 14th.

Regeneron Pharmaceuticals News Summary

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: TD Cowen raised its price target to $980 from $960 while maintaining a positive view of Regeneron, signaling potential upside from current levels. TD Cowen raises target for Regeneron stock
• Positive Sentiment: Analysts and investors continue to point to Regeneron’s growth potential, including strong Dupixent performance and positive Phase 3 OPTIMA results for investigational pasatru in fibrodysplasia ossificans progressiva. The company is also working to build a broader global oncology business. Regeneron growth potential analysis
• Neutral Sentiment: Regeneron is scheduled to report quarterly results next week. Analysts expect earnings to grow, but the company reportedly lacks the typical combination of estimate revisions and other indicators associated with a likely earnings beat, creating uncertainty ahead of the release. Regeneron earnings expectations
• Neutral Sentiment: Recent coverage describes REGN as a relatively steady stock and notes that it gained in the prior session, although it lagged some competitors. This provides limited new information about the company’s fundamentals. Regeneron stock performance versus competitors
• Negative Sentiment: Valuation-related commentary asks whether Regeneron is priced too highly relative to pharmaceutical peers, which could limit near-term upside and encourage profit-taking ahead of earnings. Regeneron valuation versus rivals

Insider Buying and Selling

In related news, Director Kathryn Guarini sold 400 shares of the company's stock in a transaction that occurred on Wednesday, September 2nd. The stock was sold at an average price of $850.00, for a total value of $340,000.00. Following the transaction, the director directly owned 603 shares in the company, valued at approximately $512,550. This represents a 39.88% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Andrew J. Murphy sold 4,147 shares of the company's stock in a transaction on Wednesday, October 14th. The shares were sold at an average price of $772.70, for a total value of $3,204,386.90. Following the completion of the transaction, the insider directly owned 47,833 shares in the company, valued at approximately $36,960,559.10. This trade represents a 7.98% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 8,093 shares of company stock valued at $6,506,845 over the last 90 days. Insiders own 6.97% of the company's stock.

Institutional Investors Weigh In On Regeneron Pharmaceuticals

A number of institutional investors have recently made changes to their positions in the stock. BlackRock Inc. purchased a new stake in shares of Regeneron Pharmaceuticals during the 2nd quarter worth approximately $5,682,636,000. Legal & General Group Plc acquired a new position in shares of Regeneron Pharmaceuticals in the 2nd quarter valued at $473,872,000. Bank of New York Mellon Corp acquired a new position in shares of Regeneron Pharmaceuticals in the 2nd quarter valued at $472,950,000. Deutsche Bank AG purchased a new position in shares of Regeneron Pharmaceuticals in the 2nd quarter valued at $323,249,000. Finally, Man Group plc purchased a new position in shares of Regeneron Pharmaceuticals in the 2nd quarter valued at $272,460,000. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Price Performance

Shares of NASDAQ REGN opened at $805.02 on Friday. The business has a 50-day simple moving average of $791.86 and a two-hundred day simple moving average of $723.16. The company has a market cap of $82.88 billion, a PE ratio of 19.90, a P/E/G ratio of 1.36 and a beta of 0.16. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.78 and a current ratio of 3.34. Regeneron Pharmaceuticals has a fifty-two week low of $575.93 and a fifty-two week high of $859.34.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last released its earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share for the quarter, topping the consensus estimate of $10.16 by $4.13. The company had revenue of $4.29 billion for the quarter, compared to the consensus estimate of $3.82 billion. Regeneron Pharmaceuticals had a net margin of 27.86% and a return on equity of 13.47%. Regeneron Pharmaceuticals's revenue was up 16.7% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $12.81 EPS. As a group, equities analysts expect that Regeneron Pharmaceuticals will post 49.10 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Monday, August 31st. Stockholders of record on Tuesday, August 18th were given a $0.94 dividend. The ex-dividend date was Tuesday, August 18th. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.5%. Regeneron Pharmaceuticals's dividend payout ratio is 9.29%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses genetic and antibody-based research technologies to develop treatments in areas including eye diseases, allergic and inflammatory conditions, cancer, cardiovascular disease, infectious diseases and rare disorders.

Its marketed products include Eylea and Eylea HD for retinal diseases, Dupixent for several inflammatory and allergic conditions, Libtayo for certain cancers, Praluent for cardiovascular disease, Kevzara for rheumatoid arthritis, and other medicines such as Inmazeb, Evkeeza, Veopoz and Arcalyst.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.